FP
VRTX icon

Foundry Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Foundry Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-699
Closed -$203K – 438
2020
Q2 		$203K Buy
+699
New +$190K 0.01% 380
2016
Q4 		– Sell
-10,261
Closed -$895K – 451
2016
Q3 		$895K Buy
10,261
+2,736
+36% +$259K 0.05% 308
2016
Q2 		$647K Sell
7,525
-1,065
-12% -$92K 0.04% 308
2016
Q1 		$683K Sell
8,590
-33,895
-80% -$3.07M 0.07% 197
2015
Q4 		$5.35M Buy
+42,485
New +$5.13M 0.44% 80

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Foundry Partners's VRTX Position: Q3 2020 in Review

Foundry Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2020, closing a stake of 699 shares — an estimated $203K sold.

Foundry Partners first reported a position in VRTX in Q4 2015 and held it in 5 quarters. The position peaked at $5.35M in Q4 2015. 951 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

  • Foundry Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Foundry Partners sold 699 Vertex Pharmaceuticals shares in Q3 2020, an estimated $203K.
  • Foundry Partners first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 5 quarters.
  • Foundry Partners's Vertex Pharmaceuticals position peaked at $5.35M in Q4 2015.
  • 951 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Foundry Partners's 13F filing for Q3 2020, filed 23 Oct 2020.